poisar

Stocks · News reference

Recursion Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.

Aug 5, 2026, 1:07 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RXRX
Source
benzinga
Observed
Aug 5, 2026, 1:07 PM
Checked
Aug 5, 2026, 1:07 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 25, 2026, 4:46 PMBcc Research

    AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

    Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

    Read original at globenewswire-inc
    MRKRHHBYBMYCELGRNVS
  4. Aug 6, 2026, 2:52 PMBcc Research

    AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine

    Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.

    Read original at globenewswire-inc
    ILMNTMOABIOBIO.B